Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly Director J. Erik Fyrwald acquired 9.336 shares of common stock, deferring cash compensation into stock units under the company's Directors' Deferral Plan.

Summary

• J. Erik Fyrwald, a Director at Eli Lilly & Co. (LLY), acquired 9.336 shares of common stock.
• The transaction occurred on December 15, 2025, at a price of $1,062.19 per share.
• These shares were acquired by deferring cash compensation and are held as stock units under the Lilly Directors' Deferral Plan.
• The stock units will be settled in shares of common stock following Fyrwald's separation from service.
• Following this transaction, Fyrwald beneficially owns 75,101.227 shares directly.

Sentiment

Score: 7

Explanation: A director increasing their stake, even through deferred compensation, is generally seen as a positive sign of confidence and alignment with shareholder interests. It's a routine transaction, not a major market mover, but inherently positive.

Positives

• Director J. Erik Fyrwald increased his beneficial ownership in Eli Lilly & Co. by acquiring 9.336 shares of common stock.
• The deferral of cash compensation into stock units aligns the director's interests with those of shareholders, indicating confidence in the company's long-term performance.

Future Outlook

The acquired stock units will be settled in shares of common stock following the reporting person's separation from service.

Management Comments

• At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

This transaction represents a routine insider filing where a director defers cash compensation into company stock, a common practice across many industries, including pharmaceuticals, to align director incentives with long-term shareholder value. It reflects standard corporate governance practices.

Comparison to Industry Standards

• Many large pharmaceutical companies, including peers like Pfizer or Merck, offer similar deferred compensation plans for directors to encourage long-term alignment with shareholder value.
• The practice of deferring cash compensation into equity is a common corporate governance mechanism, widely adopted to foster a sense of ownership and commitment among board members.

Corporate Governance

Related Party Transactions

• Acquisition of common stock units by Director J. Erik Fyrwald through the Lilly Directors' Deferral Plan in lieu of cash compensation.

Stakeholder Impact

• Shareholders: Potentially positive, as it indicates director confidence and alignment with long-term company performance.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Settlement of stock units into common stock upon the reporting person's separation from service.

Key Dates

Recommendation

This Form 4 filing details a routine deferred compensation transaction by a director, which is a positive signal of alignment but not a significant catalyst for a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance for existing investors, indicating stable corporate governance practices.

Keywords

Eli Lilly, LLY, Form 4, insider transaction, director compensation, stock acquisition, deferred compensation, J. Erik Fyrwald